1. Home
  2. GLAD vs EDIT Comparison

GLAD vs EDIT Comparison

Compare GLAD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Capital Corporation

GLAD

Gladstone Capital Corporation

HOLD

Current Price

$18.64

Market Cap

427.9M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.65

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLAD
EDIT
Founded
2001
2013
Country
United States
United States
Employees
65
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
427.9M
432.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GLAD
EDIT
Price
$18.64
$2.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$22.33
$5.30
AVG Volume (30 Days)
153.9K
3.5M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
9.78%
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$15.16
N/A
Revenue Next Year
$5.10
N/A
P/E Ratio
$11.70
N/A
Revenue Growth
N/A
132.64
52 Week Low
$16.54
$1.66
52 Week High
$29.50
$4.54

Technical Indicators

Market Signals
Indicator
GLAD
EDIT
Relative Strength Index (RSI) 42.75 48.33
Support Level $18.06 $2.65
Resistance Level $18.94 $2.73
Average True Range (ATR) 0.43 0.24
MACD -0.07 -0.03
Stochastic Oscillator 16.16 29.31

Price Performance

Historical Comparison
GLAD
EDIT

About GLAD Gladstone Capital Corporation

Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: